SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-255618
Filing Date
2021-08-25
Accepted
2021-08-25 08:06:31
Documents
12
Period of Report
2021-08-25
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d205496d8k.htm   iXBRL 8-K 31780
  Complete submission text file 0001193125-21-255618.txt   156826

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA ctic-20210825.xsd EX-101.SCH 2904
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE ctic-20210825_lab.xml EX-101.LAB 18139
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ctic-20210825_pre.xml EX-101.PRE 11416
5 EXTRACTED XBRL INSTANCE DOCUMENT d205496d8k_htm.xml XML 3440
Mailing Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121
Business Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121 2062827100
CTI BIOPHARMA CORP (Filer) CIK: 0000891293 (see all company filings)

IRS No.: 911533912 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-28386 | Film No.: 211203665
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences